Concepedia

Pediatric phase 2 trial of a WEE1 inhibitor, adavosertib (AZD1775), and irinotecan for relapsed neuroblastoma, medulloblastoma, and rhabdomyosarcoma

Kristina A. Cole, Heba Ijaz, Lea F. Surrey, Mariarita Santi, Xiaowei Liu, Charles G. Minard, John M. Maris, Stephan D. Voss, Joel M. Reid, Elizabeth Fox,

Cancer · 2023 · 28 citations · 33 references

DOIFull text

Open access

Abstract

This is first phase 2 clinical trial of adavosertib in pediatrics and the first with irinotecan. The combination may be of sufficient activity to consider further study of adavosertib in neuroblastoma.

References

33

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 28.6K citations

, , +9

Highly multiplexed immunofluorescence imaging of human tissues and tumors using t-CyCIF and conventional optical microscopes

Jia‐Ren Lin, Benjamin Izar, Shu Wang et al. · eLife · 2018 · 715 citations · Full text

, , +20

Association of Age at Diagnosis and Genetic Mutations in Patients With Neuroblastoma

Nai‐Kong V. Cheung · JAMA · 2012 · 464 citations · Full text

Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With <i>TP53</i>-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months

Suzanne Leijen, Robin M.J.M. van Geel, Gabe S. Sonke et al. · Journal of Clinical Oncology · 2016 · 328 citations · Full text

, , +15

ATRX loss promotes tumor growth and impairs nonhomologous end joining DNA repair in glioma

Carl Koschmann, Anda‐Alexandra Calinescu, Felipe J. Núñez et al. · Science Translational Medicine · 2016 · 297 citations · Full text